
PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC
As radiopharmaceuticals gain traction beyond the post-chemotherapy setting for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), evolving criteria for prostate-specific membrane antigen (PSMA) PET use may help clarify …